Barium sulphate belongs to the radiopaque contrast media class of medicines. The material coats the stomach, intestine, and esophagus to locate the diseases or damaged areas. Since it does not get absorbed by the blood, it is able to provide better results upon running a radiology scan. In Canada, with growing awareness and increasing side effects of other-iodinated oral contrast media, barium sulphate has been emerging as an optimal substitute with lower side effects. The prime reason which is projected to drive the market growth of the barium sulphate market for contract media in the country is booming radiology requirements owing to the rising advent of non-communicable and chronic diseases. Data from the Canadian Government shows that 44% of adults who belong to the age group of 20 to 64 years suffer from at least 1 chronic disease. More than 14% of adults suffer from Osteoporosis while over 10% suffer from chronic obstructive pulmonary disease. Furthermore, 8% of the population in the age group suffer from cancer or a significant threat of cancer. The booming threat of chronic diseases has notably increased the government expenditure on diagnosis and treatment, creating a robust lucrative demand for radiology, hence providing potential for barium sulphatic as a contrast media. Furthermore, continuous research in the sector for contrast media with the least side effects creates huge opportunities for barium sulphate.
A study conducted by the Radiology Society of North America (RSNA) over a subject size of 200 patients undergoing regular CT scans for oncology treatment observed that on given a choice over, 85.5% of the patients preferred iodinated oral contrast medium, 7.5% preferred Barium sulphate alternative, showing changing attitude towards barium sulphate. It was concluded that barium sulphate contract media can substitute for other contrast media. With the rise in awareness and growing radiology procedures, it is forecasted that barium sulphate has promising market prospect in the country.
The rising prevalence of chronic diseases and booming expenditure on healthcare has supported regular diagnosis and testing for early detection and better treatment has notably increased the CT scan procedures in the country. Furthermore, rising governmental healthcare expenditure to uplift people's standard of living has supported the installation of new CT scan machines. Barium Sulphate has witnessed a significant growth as a contrast media during CT scans owing to the clarity of diagnosis they provide. It is forecasted that with the rise in CT scan procedures and the installation of new CT scans, the demand for barium sulphate for contrast media will emerge at a lucrative rate.
Rising governmental investment and booming out-of-pocket expenditure are fueling the CT scan market, hence creating noteworthy potential for the market. VoLumen and Readi-Cat-2 are the leading barium sulphate-based contrast media dose used in the country for the CT scan procedure, having 0.1 g and 9g to 18g of barium sulphate, respectively, in 100 ml and 450 ml to 900 ml of dose.
Key Developments:
| Report Metric | Details |
| Growth Rate | CAGR during the forecast period |
| Base Year | 2020 |
| Forecast Period | 2022–2027 |
| Forecast Unit (Value) | USD Billion |
| Segments Covered | Method Of Administration, Procedure, End-User, And Province |
| Regions Covered |
Alberta , British Columbia, Ontario, Others |
| Companies Covered | Bracco S.p.A., Guerbet, Voyageur Pharma, Merck & Co., Inc. |
| Customization Scope | Free report customization with purchase |
Segmentation